Attenuated Plasmodium yoelii lacking purine nucleoside phosphorylase confer protective immunity

Nature Medicine

Volumn 14, Issue 9, 2008, Pages 954-958

  Ting, Li Min ^a   Gissot, Mathieu ^a   Coppi, Alida ^b   Sinnis, Photini ^b   Kim, Kami ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; MALARIA VACCINE; PURINE; PURINE NUCLEOSIDE PHOSPHORYLASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME SPECIFICITY; GAMETOCYTE; IMMUNITY; IN VIVO STUDY; INOCULATION; MALARIA; MIDGUT; MOSQUITO; MOUSE; NONHUMAN; OOCYTE; PLASMODIUM YOELII; PRIORITY JOURNAL;

ANIMALS; CLONING, MOLECULAR; DNA PRIMERS; FEMALE; LIFE CYCLE STAGES; MALARIA; MALARIA VACCINES; MICE; MICE, INBRED BALB C; PHENOTYPE; PLASMODIUM; PURINE-NUCLEOSIDE PHOSPHORYLASE;

MUS; PLASMODIUM YOELII;

EID: 51349118056     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.1867     Document Type: Article

References (30)

1. Kicska, G.A. et al. Transition state analogue inhibitors of purine nucleoside phosphorylase from Plasmodium falciparum. J. Biol. Chem. 277, 3219-3225 (2002).
2. Kicska, G.A. et al. Purine-less death in Plasmodium falciparum induced by immucillin-H, a transition state analogue of purine nucleoside phosphorylase. J. Biol. Chem. 277, 3226-3231 (2002).
3. Shi, W. et al. Plasmodium falciparum purine nucleoside phosphorylase: crystal structures, immucillin inhibitors and dual catalytic function. J. Biol. Chem. 279, 18103-18106 (2004).
4. Ting, L.M. et al. Targeting a novel Plasmodium falciparum purine recycling pathway with specific immucillins. J. Biol. Chem. 280, 9547-9554 (2005).
5. Snow, R., Craig, M., Deichmann, U. & Marsh, K. Estimating mortality, morbidity and disability due to malaria among Africa's non-pregnant population. Bull. World Health Organ. 77, 624-640 (1999).
6. Reyes, P. et al. Enzymes of purine and pyrimidine metabolism from the human malaria parasite, Plasmodium falciparum. Mol. Biochem. Parasitol. 5, 275-290 (1982).
7. Muller, S. et al. In the human malaria parasite Plasmodium falciparum, polyamines are synthesized by a bifunctional ornithine decarboxylase, S-adenosylmethionine decarboxylase. J. Biol. Chem. 275, 8097-8102 (2000).
8. Muller, S., Coombs, G.H. & Walter, R.D. Targeting polyamines of parasitic protozoa in chemotherapy. Trends Parasitol. 17, 242-249 (2001).
9. Wrenger, C., Luersen, K., Krause, T., Muller, S. & Walter, R.D. The Plasmodium falciparum bifunctional ornithine decarboxylase, S-adenosyl-l-methionine decarboxylase, enables a well balanced polyamine synthesis without domain-domain interaction. J. Biol. Chem. 276, 29651-29656 (2001).
10. Burkot, T.R., Graves, P.M., Paru, R., Wirtz, R.A. & Heywood, P.F. Human malaria transmission studies in the Anopheles punctulatus complex in Papua New Guinea: sporozoite rates, inoculation rates and sporozoite densities. Am. J. Trop. Med. Hyg. 39, 135-144 (1988).
11. Weiss, W.R., Good, M.F., Hollingdale, M.R., Miller, L.H. & Berzofsky, J.A. Genetic control of immunity to Plasmodium yoelii sporozoites. J. Immunol. 143, 4263-4266 (1989).
12. Weiss, W.R. Host-parasite interactions and immunity to irradiated sporozoites. Immunol. Lett. 25, 39-42 (1990).
13. Khan, Z.M. & Vanderberg, J.P. Role of host cellular response in differential susceptibility of nonimmunized BALB/c mice to Plasmodium berghei and Plasmodium yoelii sporozoites. Infect. Immun. 59, 2529-2534 (1991).
14. Hoffman, S.L. et al. Immune response gene regulation of immunity to Plasmodium berghei sporozoites and circumsporozoite protein vaccines. Overcoming genetic restriction with whole organism and subunit vaccines. J. Immunol. 142, 3581-3584 (1989).
15. Mota, M.M., Thathy, V., Nussenzweig, R.S. & Nussenzweig, V. Gene targeting in the rodent malaria parasite Plasmodium yoelii. Mol. Biochem. Parasitol. 113, 271-278 (2001).
16. Jongco, A.M., Ting, L.M., Thathy, V., Mota, M.M. & Kim, K. Improved transfection and new selectable markers for the rodent malaria parasite Plasmodium yoelii. Mol. Biochem. Parasitol. 146, 242-250 (2006).
17. Ecker, A., Moon, R., Sinden, R.E. & Billker, O. Generation of gene targeting constructs for Plasmodium berghei by a PCR-based method amenable to high throughput applications. Mol. Biochem. Parasitol. 145, 265-268 (2006).
18. Kadekoppala, M., Kline, K., Akompongm, T. & Haldar, K. Stable expression of a new chimeric fluorescent reporter in the human malaria parasite Plasmodium falciparum. Infect. Immun. 68, 2328-2332 (2000).
19. Menard, R. et al. Circumsporozoite protein is required for development of malaria sporozoites in mosquitoes. Nature 385, 336-340 (1997).
20. Wykes, M. & Good, M.F. A case for whole-parasite malaria vaccines. Int. J. Parasitol. 37, 705-712 (2007).
21. Hoffman, S.L. et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J. Infect. Dis. 185, 1155-1164 (2002).
22. Luke, T.C. & Hoffman, S.L. Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J. Exp. Biol. 206, 3803-3808 (2003).
23. Mueller, A.K., Labaied, M., Kappe, S.H. & Matuschewski, K. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 433, 164-167 (2005).
24. Makobongo, M.O. et al. The purine salvage enzyme hypoxanthine guanine xanthine phosphoribosyl transferase is a major target antigen for cell-mediated immunity to malaria. Proc. Natl. Acad. Sci. USA 100, 2628-2633 (2003).
25. Pombo, D.J. et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 360, 610-617 (2002).
26. Sambandamurthy, V.K. & Jacobs, W.R., Jr. Live attenuated mutants of Mycobacterium tuberculosis as candidate vaccines against tuberculosis. Microbes Infect. 7, 955-961 (2005).
27. Scheller, L.F. & Azad, A.F. Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites. Proc. Natl. Acad. Sci. USA 92, 4066-4068 (1995).
28. Bejon, P. et al. Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J. Infect. Dis. 191, 619-626 (2005).
29. El Bissati, K. et al. The plasma membrane permease PfNT1 is essential for purine salvage in the human malaria parasite Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 103, 9286-9291 (2006).
30. Sultan, A.A. et al. TRAP is necessary for gliding motility and infectivity of Plasmodium sporozoites. Cell 90, 511-522 (1997).